Markets Gone Wild

Biodexa’s Successful Type C Meeting with FDA: A Major Milestone in the Development of eRapa for Familial Adenomatous Polyposis Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, recently announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the planned registrational Phase 3 study of eRapa in Familial…

Cohen & Steers Announces 5.1% Increase in Quarterly Dividend In a recent press release, the Board of Directors of Cohen & Steers, Inc. (CNS) announced an increase in the cash dividend for the first quarter of 2025. The dividend will amount to $0.62 per share of common stock, marking a 5.1% increase from the $0.59…

Understanding the Securities Class Action: A Potential Recovery for Investors in Ready Capital Corporation Investors who have experienced financial losses as a result of their investment in Ready Capital Corporation (NYSE:RC) may be entitled to participate in a securities class action lawsuit. This type of legal action allows a large group of individuals or institutions…

Exciting Times Ahead for Selinexor: A Deep Dive into XPOVIO’s Financial Performance and Clinical Trials It’s an intriguing time for the biopharmaceutical industry, with new treatments and innovations popping up left and right. One such development comes from Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company specializing in the discovery and development of novel XPO1 inhibitors,…